Effects of Telmisartan on Arterial Stiffness Assessed by the Cardio-ankle Vascular Index in Hypertensive Patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12610000125022

Enrollment

100

Registered

2010-02-08

Start date

2007-01-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Arterial stiffness is an independent prognostic predictor of cardiovascular morbidity and mortality. This study was conducted to determine the effect of telmisartan on the cardio-ankle vascular index (CAVI), a novel blood pressure (BP)-independent marker for arterial stiffness in hypertensive patients.

Interventions

a) Patients treated with telmisartan-based therapy were first treated with 20mg/day of telmisartan for 4 weeks. If after this time the target BP was not attained it was then subsequently increased up to a maximum dose of 80 mg/day until the target BP was attained. Additional antihypertensive agents other than renin-angiotensin system (RAS) inhibitors were added unless the blood pressure (BP) fell below the target BP. b) the duration is 1 year. c) the mode of administration is oral capsule.

Study design

Allocation

Randomised controlled trial

Primary purpose

Treatment

Eligibility

Sex/Gender

All

Age

20 Years to 75 Years

Healthy volunteers

Inclusion criteria

hypertensive patients with arterial stiffness and untreated hypertension or uncontrollable hypertension treated with medications other than renin-angiotensin system (RAS) inhibitors

Exclusion criteria

patients with already taking RAS inhibitors

Outcome results